CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Decibel Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Decibel Therapeutics, Inc.
1325 Boylston Street, Suite 500
Phone: (617) 370-8701p:617 370-8701 BOSTON, MA  02215  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 9/25/2023.
This company ceased filing statements with the SEC on 10/10/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Decibel Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing transformative treatments for hearing and balance disorder. It is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The Company has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board William H.Carson 64 5/1/2021 5/1/2021
President, Chief Executive Officer, Director Laurence E.Reid 59 1/1/2020 1/1/2020
Interim Chief Financial Officer James B.Murphy 67 10/7/2022 10/7/2022
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Decibel Securities Corporation
Decibel Therapeutics Australia Pty Ltd
Taligen Therapeutics, Inc.

General Information
Number of Employees: 68 (As of 12/31/2022)
Outstanding Shares: 25,126,935 (As of 8/4/2023)
Shareholders: 86
Stock Exchange: NASD
Federal Tax Id: 464198709
Fax Number: (302) 655-5049
Email Address: info@decibeltx.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024